Connecticut's last medical-only cannabis dispensary, Bluepoint Wellness in Westport, plans to relocate within the town after repeated rejections for recreational sales. This move signals the potential close of the state's medical-only era unless local zoning changes. With most dispensaries already hybrid, the shift underscores tensions between local control and statewide market trends.
Zoning Blocks Expansion in Westport
Westport's Planning and Zoning Commission has denied Bluepoint's requests to sell recreational products, citing traffic concerns after amending its code in 2021 to ban such businesses. Opened in late 2019, Bluepoint remains the outlier among Connecticut's 61 licensed stores, where 29 now offer both medical and recreational cannabis. Co-founder Nick Tamborrino highlighted the frustration in 2023, noting daily turnaways of local residents seeking recreational options.
The company responded by launching Venu Flower Collective, a recreational store 50 miles away in Middletown. Bluepoint now relocates its medical dispensary within Westport for 18 to 24 months before shifting to an unidentified town for hybrid operations, according to CT Insider. Without zoning updates, this could eliminate Connecticut's sole medical-only outlet.
Medical Market Contracts Under Recreational Pressure
Recreational sales launched in 2023, driving medical patient numbers down from nearly 49,000 to under 32,000. Annual medical sales fell $21 million in 2025, with transactions dropping from 2.6 million in 2024 to 2.2 million the next year. Fine Fettle's chief operating officer Ben Zachs observed that sustaining medical-only models grows harder amid these changes.
State cannabis ombudsman Erin Gorman Kirk points to high prices, inconsistent quality, and limited variety—especially compared to neighbors Massachusetts and Rhode Island—as factors eroding medical demand. Local zoning like Westport's amplifies this pressure, forcing operators toward hybrid models for viability.
Implications for Access and Policy
The decline raises questions about medical cannabis access for patients reliant on its tailored programs. Hybrid stores serve broader markets but may prioritize recreational volume, potentially altering product availability or pricing for qualifying patients. Connecticut's experience reflects national patterns post-legalization, where recreational dominance reshapes medical infrastructure.
Bluepoint's path illustrates how municipal rules can dictate statewide trends, prompting debates over balancing community concerns with economic realities in cannabis policy.
